Suppr超能文献

韩国炎症性肠病患者 COVID-19 的临床病程:KASID 多中心研究。

Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study.

机构信息

Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

出版信息

J Korean Med Sci. 2021 Dec 13;36(48):e336. doi: 10.3346/jkms.2021.36.e336.

Abstract

In 2020, the novel coronavirus disease 2019 (COVID-19) began to spread worldwide and remains an ongoing medical challenge. This case series reports on the clinical features and characteristics of patients with inflammatory bowel disease (IBD) and confirmed COVID-19 infection. From February 2020 to March 2021, nine patients with IBD had confirmed COVID-19 across four hospitals in Korea. The median age at COVID-19 diagnosis was 42 years. Six patients were male, and seven patients had ulcerative colitis (UC). No patients required oxygen therapy, intensive care unit hospitalizations, or died. The most common symptom was fever, and gastrointestinal (GI) symptoms developed as diarrhea in five patients with UC. Oral steroids were used to combat UC aggravation in two patients. In this case series of nine IBD patients diagnosed with COVID-19 in Korea, the clinical presentation was predominately a mild respiratory tract infection. Most patients with UC developed new GI symptoms including diarrhea.

摘要

2020 年,新型冠状病毒病 2019(COVID-19)开始在全球范围内传播,仍然是一个持续存在的医学挑战。本病例系列报告了炎症性肠病(IBD)和确诊 COVID-19 感染患者的临床特征和特点。从 2020 年 2 月至 2021 年 3 月,韩国的四家医院共收治了 9 例确诊 COVID-19 的 IBD 患者。COVID-19 诊断时的中位年龄为 42 岁。6 名患者为男性,7 名患者患有溃疡性结肠炎(UC)。没有患者需要氧疗、入住重症监护病房或死亡。最常见的症状是发热,5 例 UC 患者出现腹泻等胃肠道(GI)症状。有 2 例患者使用口服类固醇治疗 UC 加重。在这项韩国 9 例确诊 COVID-19 的 IBD 患者的病例系列研究中,临床表现主要为轻度呼吸道感染。大多数 UC 患者出现包括腹泻在内的新的胃肠道症状。

相似文献

1
Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study.
J Korean Med Sci. 2021 Dec 13;36(48):e336. doi: 10.3346/jkms.2021.36.e336.
2
Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.
PLoS One. 2021 Oct 5;16(10):e0258271. doi: 10.1371/journal.pone.0258271. eCollection 2021.
3
Ulcerative colitis as a possible sequela of COVID-19 Infection: The endless story.
Arab J Gastroenterol. 2022 May;23(2):134-137. doi: 10.1016/j.ajg.2022.01.006. Epub 2022 Feb 10.
4
Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis.
United European Gastroenterol J. 2021 Mar;9(2):159-176. doi: 10.1177/2050640620972602. Epub 2021 Mar 23.
5
COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
J Gastroenterol Hepatol. 2021 Nov;36(11):3033-3040. doi: 10.1111/jgh.15588. Epub 2021 Jul 5.
6
Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis.
J Dig Dis. 2016 Sep;17(9):610-617. doi: 10.1111/1751-2980.12397.
8
Disease Flares Following COVID-19 Vaccination in Patients with Inflammatory Bowel Disease.
Intern Med. 2023 Dec 15;62(24):3579-3584. doi: 10.2169/internalmedicine.2335-23. Epub 2023 Sep 29.
9
The natural history of COVID-19 in vaccinated inflammatory bowel disease patients.
Dig Liver Dis. 2023 Mar;55(3):305-309. doi: 10.1016/j.dld.2022.12.012. Epub 2023 Jan 17.
10
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Aliment Pharmacol Ther. 2021 Dec;54(11-12):1432-1441. doi: 10.1111/apt.16663. Epub 2021 Oct 25.

引用本文的文献

1
Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea.
Front Med (Lausanne). 2023 Jun 20;10:1185300. doi: 10.3389/fmed.2023.1185300. eCollection 2023.
2
Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.
Int J Colorectal Dis. 2022 Nov;37(11):2277-2289. doi: 10.1007/s00384-022-04265-w. Epub 2022 Oct 22.
3
Impact of COVID-19 Pandemic on the Quality of Life of IBD Patients.
Medicina (Kaunas). 2022 Apr 19;58(5):562. doi: 10.3390/medicina58050562.

本文引用的文献

1
No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.
Clin Gastroenterol Hepatol. 2021 Nov;19(11):2312-2314.e3. doi: 10.1016/j.cgh.2021.06.008. Epub 2021 Jun 5.
3
Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden.
United European Gastroenterol J. 2021 Mar;9(2):177-192. doi: 10.1002/ueg2.12049. Epub 2021 Mar 11.
5
Comparison of the second and third waves of the COVID-19 pandemic in South Korea: Importance of early public health intervention.
Int J Infect Dis. 2021 Mar;104:742-745. doi: 10.1016/j.ijid.2021.02.004. Epub 2021 Feb 5.
7
Management of inflammatory bowel disease in the COVID-19 era.
Intest Res. 2022 Jan;20(1):3-10. doi: 10.5217/ir.2020.00156. Epub 2021 Feb 3.
8
Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population.
Dig Liver Dis. 2021 Mar;53(3):263-270. doi: 10.1016/j.dld.2020.12.013. Epub 2020 Dec 26.
9
Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Intest Res. 2022 Jan;20(1):134-143. doi: 10.5217/ir.2020.00108. Epub 2021 Jan 18.
10
Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis.
United European Gastroenterol J. 2021 Mar;9(2):159-176. doi: 10.1177/2050640620972602. Epub 2021 Mar 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验